Comparing the Impact of Mindful Interoceptive Mapping and Mindful Breathing on Pain and Opioid Use
- Conditions
- Pain, ChronicOpioid Use
- Interventions
- Behavioral: Mindfulness of BreathBehavioral: Mindful Interoceptive Mapping
- Registration Number
- NCT04523766
- Lead Sponsor
- University of Utah
- Brief Summary
This is a single site, two-arm, parallel group randomized clinical trial comparing the effect of two mindfulness-based interventions (Mindful Interoceptive Mapping vs. Mindfulness of the Breath) on opioid-treated chronic pain patients' pleasant/unpleasant sensation reports and opioid use.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 149
- (1) men/women ≥18 years of age,
- (2) current chronic low back pain condition determined by physician assessment (e.g., ICD-10 codes M54.5, M54.4, M54.3),
- (3) reporting pain ≥3 on 0-10 scale with opioid medication, and
- (4) long-term opioid pharmacotherapy (>3 months of use).
- (1) formal mindfulness training (e.g., MBSR/MBRP),
- (2) current cancer diagnosis,
- (3) psychosis, suicidality, and moderate/severe substance use disorder in the past year as assessed with the MINI, and
- (4) unstable illness, as judged by a physician, that may interfere with treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mindfulness of Breath Mindfulness of Breath - Mindful Interoceptive Mapping Mindful Interoceptive Mapping -
- Primary Outcome Measures
Name Time Method Immediate Change in Pleasant Sensation Ratios Immediately before and immediately after the final mindfulness training session, approximately 30 minutes The Multidimensional Assessment of Pleasant and Painful Sensations (MAPPS) is an outline of a human body overlaid by a grid of 786 sensation pixels that was developed using the Qualtrics online survey platform, which can be recreated on any device capable of supporting a web-browser. Mouse clicks allow respondents to identify locations (i.e., grid pixels) on the manikin where they feel both pleasant and unpleasant sensations. Clicking once in any grid pixel turns that location blue, indicating a pleasant sensation. Clicking twice in any grid pixel turns that location red, indicating an unpleasant sensation. A ratio of pleasant to unpleasant sensations is derived from MAPPS.
Longer-Term Change in Pleasant Sensation Ratios At baseline and posttreatment, approximately 1.5 months The Multidimensional Assessment of Pleasant and Painful Sensations (MAPPS) is an outline of a human body overlaid by a grid of 786 sensation pixels that was developed using the Qualtrics online survey platform, which can be recreated on any device capable of supporting a web-browser. Mouse clicks allow respondents to identify locations (i.e., grid pixels) on the manikin where they feel both pleasant and unpleasant sensations. Clicking once in any grid pixel turns that location blue, indicating a pleasant sensation. Clicking twice in any grid pixel turns that location red, indicating an unpleasant sensation. A ratio of pleasant to unpleasant sensations is derived from MAPPS.
- Secondary Outcome Measures
Name Time Method Change in Opioid Medication Desire Immediately before and immediately after the final mindfulness training session, approximately 30 minutes Single-item Numeric Rating Scale (0-10), with 0 indicating no desire for opioid medication and 10 representing the an intense desire for opioid medication.
Change in Pain Functional Interference At pretreatment and 1-month follow-up, approximately 3 months Pain functional interference will be assessed with the Brief Pain Inventory.
Change in Pain Intensity Immediately before and immediately after the final mindfulness training session, approximately 30 minutes Single-item Numeric Rating Scale (0-10), with 0 indicating no pain and 10 representing the an most intense pain imaginable.
Change in Opioid Use At baseline and 1-month follow-up, approximately 3 months Opioid Use will be assessed with a timeline follow-back procedure.
Trial Locations
- Locations (1)
University of Utah
🇺🇸Salt Lake City, Utah, United States